• Explore /
  • Poster
  • / The dual SYK/JAK inhibitor cerdulatinib demonstrates rapid tumor responses in a phase 2 study in patients with relapsed/refractory B- and T-cell non-Hodgkin lymphoma (NHL).

The dual SYK/JAK inhibitor cerdulatinib demonstrates rapid tumor responses in a phase 2 study in patients with relapsed/refractory B- and T-cell non-Hodgkin lymphoma (NHL).

Abstract Poster

Authors

null

Paul A. Hamlin

Memorial Sloan Kettering Cancer Center, New York, NY

Paul A. Hamlin , Bruce D. Cheson , Charles Michael Farber , Tatyana Feldman , Timothy S Fenske , Brian T. Hess , James L. Khatcheressian , Carole Brennan Miller , Javier Munoz , Manish R. Patel , Sonali M. Smith , Stephen Douglas Smith , Don A. Stevens , Jing Christine Ye , Andrew Steele , Anjali Pandey , Matt Birrell , Janet Leeds , Greg Coffey , John T Curnutte

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Sub Track

Non-Hodgkin Lymphoma

Clinical Trial Registration Number

NCT01994382

Citation

J Clin Oncol 36, 2018 (suppl; abstr 7511)

DOI

10.1200/JCO.2018.36.15_suppl.7511

Abstract #

7511

Poster Bd #

148

Abstract Disclosures

Similar Posters

First Author: Erel Joffe

First Author: Kiyoshi Ando

First Author: Tamta Makharadze

First Author: Guilherme Fleury Perini